Browse > Article

Diagnostic Utility of Pleural Fluid CEA and CYFRA 21-1 for Malignant Pleural Effusions  

Chung, Jae Ho (Department of Internal Medicine, Kwandong University College of Medicine, Myungji Hospital)
Choi, Jeong Eun (Department of Internal Medicine, Kwandong University College of Medicine, Myungji Hospital)
Park, Moo Suk (Department of Internal Medicine, Yonsei University College of Medicine)
Hwang, Sang Yon (Department of Internal Medicine, Yonsei University College of Medicine)
Moon, Jin Wook (Department of Internal Medicine, Yonsei University College of Medicine)
Kim, Young Sam (Department of Internal Medicine, Yonsei University College of Medicine)
Chang, Joon (Department of Internal Medicine, Yonsei University College of Medicine)
Kim, Joo Hang (Department of Internal Medicine, Yonsei University College of Medicine)
Kim, Sung Kyu (Department of Internal Medicine, Yonsei University College of Medicine)
Kim, Se Kyu (Department of Internal Medicine, Yonsei University College of Medicine)
Publication Information
Tuberculosis and Respiratory Diseases / v.57, no.1, 2004 , pp. 32-36 More about this Journal
Abstract
Background : The purpose of this study was to evaluate the usefulness of the pleural fluid carcinoembryonic antigen (CEA) and cytokeratin fragment 19 (CYFRA 21-1) tumor markers as complementary tools for the diagnosis of malignant pleural effusions. Patients and Methods : The levels of pleural and serum CEA and CYFRA 21-1 were prospectively assayed in 222 patients with pleural effusions (150 benign effusions, 57 bronchogenic carcinomas and 15 metastatic carcinomas). Results : The levels of pleural fluid CEA and CYFRA 21-1 in the malignant effusions were significantly higher than those in the benign effusions. With a specificity of 95%, the cut off values for the CEA and CYFRA 21-1 in pleural effusions were 5 and 89 ng/ml, respectively. The diagnostic sensitivities of the pleural fluid CEA and CYFRA 21-1 in malignant effusions were 72 and 54%, respectively, whereas using a combination of the two, the sensitivity increased to 87% (p<0.05). Conclusions : These findings suggest that a combination of the pleural fluid CEA and CYFRA 21-1 in pleural effusions can be useful in the diagnosis of malignant pleural effusions.
Keywords
CEA; CYFRA 21-1; Malignant pleural effusions;
Citations & Related Records

Times Cited By SCOPUS : 0
연도 인용수 순위
  • Reference
1 Toumbis M, Rasidakis A, Passalidou E, Kalomenidis J, Alchanatis M, Orphanidou D, et al. Evaluation of CYFRA 21-1 in malignant and benign pleuraleffusions. Anticancer Res 1996;16:2101-4
2 Satoh H, Sumi M, Yagyu H, Ishikawa H, Suyama T, Naitoh T, et al. Clinical evaluation of CYFRA 21-1 in malignant pleural fluids. Oncology 1995;52:211-4
3 Lee HJ, Lee KH, Shin KC, Shin CJ, Park HJ, Mun YC, et al. Diagnostic value of CYFRA 21-1 in differential diagnosis of pleural effusion. Tuberc RespirDis 1999;47:50-6
4 Alatas F, Alatas O, Metintas M, Colak O, Harmanci E, Demir S. Diagnostic value of CEA, CA 15-3, CA 19-9, CYFRA 21-1, NSE and TSA assay in pleuraleffusions. Lung Cancer 2001;31:9-16
5 Tamura S, Nishigaki T, Moriwaki Y, Fujioka H, Nakano T, Fujii J, et al. Tumor markers in pleural effusion diagnosis. Cancer 1988;61:298-302
6 Prakash UB, Reiman HM. Comparison of needle biopsy with cytologic analysis for the evaluation of pleural effusion: analysis of 414 cases. Mayo Clin Proc1985;60:158-64
7 Ferrer J, Villarino MA, Encabo G, Felip E, Bermejo B, Vila S, et al. Diagnostic utility of CYFRA 21-1, carcinoembryonic antigen, CA 125, neuron specificenolase, and squamous cell antigen level determinations in the serum and pleural fluid of patients with pleural effusions. Cancer 1999;86:1488-95
8 Muraki M, Tohda Y, Iwanaga T, Uejima H, Nagasaka Y, Nakajima S. Assessment of serum CYFRA 21-1 in lung cancer. Cancer 1996;77:1274-7
9 McKenna JM, Chandrasekhar AJ, Henkin RE. Diagnostic value of carcinoembryonic antigen in exudative pleural effusions. Chest 1980;78:587-90
10 Salama G, Miedouge M, Rouzaud P, Mauduyt MA, Pujazon MC, Vincent C, et al. Evaluation of pleural CYFRA 21-1 and carcinoembryonic antigen in thediagnosis of malignant pleural effusions. Br J Cancer 1998;77:472-6
11 Paganuzzi M, Onetto M, Marroni P, Filiberti R, Tassara E, Parodi S, et al. Diagnostic value of CYFRA 21-1 tumor marker and CEA in pleural effusion dueto mesothelioma. Chest 2001;119:1138-42
12 Stieber P, Hasholzner U, Bodenmuller H, Nagel D, Sunder-Plassmann L, Dienemann H, et al. CYFRA 21-1. A new marker in lung cancer. Cancer 1993;72:707-13
13 Rastel D, Ramaioli A, Cornillie F, Thirion B. CYFRA 21-1, a sensitive and specific new tumour marker for squamous cell lung cancer. Report of the firstEuropean multicentre evaluation. CYFRA 21-1 Multicentre Study Group. Eur J Cancer 1994;30A:601-6
14 Pujol JL, Grenier J, Daures JP, Daver A, Pujol H, Michel FB. Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assayas a marker of lung cancer. Cancer Res 1993;53:61-6
15 Lee JH, Jang SH, Lee HL, Kwak SM, Chang HY, Kim BI, et al. Clinical significance of the combined assay of pleural fluid ADA activity and CEA level in the various pleural effusions. Tuberc and Respir Dis 1993;40:35-42
16 Romero S, Fernandez C, Arriero JM, Espasa A, Candela A, Martin C, et al. CEA, CA 15-3 and CYFRA 21-1 in serum and pleural fluid of patients with pleural effusions. Eur Respir J 1996;9:17-23
17 Garcia-Pachon E, Padilla-Navas I, Dosda MD, Miralles-Llopis A. Elevated level of carcinoembryonic antigen in nonmalignant pleural effusions. Chest 1997;111:643-7